Establishment Labs Surpasses Three Million Motiva Devices
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has surpassed three million Motiva® devices in market.
- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has surpassed three million Motiva® devices in market.
- “Since its founding, Establishment Labs has been guided by one core principle: putting women at the center of everything we do,” said Juan José Chacón-Quirós, Establishment Labs CEO and Founder.
- We believe that by setting new standards in safety and clinical performance, we will expand markets in breast aesthetics and reconstruction.”
Establishment Labs’ 2022 Post Market Surveillance Report is available at: Motiva PMS Report . - Motiva Implants are undergoing an IDE clinical trial and are not approved for sale in the United States.